Modulation of 5-fluorouracil host toxicity by 5- (benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine

Biochemical Pharmacology

Volumn 60, Issue 3, 2000, Pages 427-431

  Ashour, Osama M ^a,b   Naguib, Fardos N M ^a   Panzica, Raymond P ^c   Al Safarjalani, Omar N ^a   El Kouni, Mahmoud H ^a  

^a Univ A   (United States)

^b MINIA UNIVERSITY   (Egypt)

^c University of Rhode Island   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Toxicity; Uridine phosphorylase inhibitor; Uridine prodrug

Indexed keywords

2',3',5' TRI O ACETYLURIDINE; 5 (BENZYLOXYBENZYL)BARBITURIC ACID ACYCLONUCLEOSIDE; ENZYME INHIBITOR; FLUOROURACIL; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG OVERDOSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTOXICATION; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BARBITURATES; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PRODRUGS; TUMOR CELLS, CULTURED; URIDINE; URIDINE PHOSPHORYLASE;

EID: 0034257227     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00342-7     Document Type: Article

References (39)

1. Klubes P., Cerna I., Meldon M.A. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol. 8:1982;17-21.
2. Martin D.S., Stolfi R.L., Sawyer R.C., Spiegelman S., Young C.W. High dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res. 42:1982;3964-3970.
3. Klubes P., Cerna I. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res. 43:1983;3182-3186.
4. Peters G.J., van Dijk J., Laurensse E., van Groeningen C.J., Lankelma J., Leyva A., Nadal J.C., Pinedo H.M. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. Br J Cancer. 57:1988;259-265.
5. Seiter K., Kemeny N., Martin D., Schneider A., Williams L., Colofiore J., Sawyer R. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer. 71:1993;1875-1881.
6. Monks A and Cysyk RL, Uridine regulation by the isolated rat liver: Perfusion with an artificial oxygen carrier. Am J Physiol 242: R465-R470, 1982.
7. Leyva A., van Groeningen C.J., Kraal I., Gall H., Peters G.J., Lankelma J., Pinedo H.M. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res. 44:1984;5928-5933.
8. van Groeningen C.J., Leyva A., Kraal I., Peters G.J., Pinedo H.M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep. 70:1986;745-750.
9. Chan T.C.K., Markman M., Pfeifle C.E., Taetle R., Abramson I., Howell S.B. Uridine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 22:1988;83-86.
10. van Groeningen C.J., Peters G.J., Leyva A., Laurensse E., Pinedo H.M. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst. 81:1989;157-162.
11. van Groeningen C.J., Peters G.J., Nadal J.C., Leyva A., Laurensse E., Pinedo H.M. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst. 83:1991;437-441.
12. van Groeningen C.J., Peters G.J., Pinedo H.M. Modulation of fluorouracil toxicity with uridine. Semin Oncol. 19:1992;148-154.
13. Sommadossi J.-P., Cretton E.M., Kidd L.B., McClure H.M., Anderson D.C., el Kouni M.H. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys Implications for chemotherapy . Cancer Chemother Pharmacol. 37:1995;14-22.
14. Ashour O.M., Naguib F.N.M., el Kouni M.H. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. Biochem Pharmacol. 51:1996;1601-1611.
15. Ashour O.M., Al Safarjalani O.N., Naguib F.N.M., Goudgaon N.M., Schinazi R.F., el Kouni M.H. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine an inhibitor of uridine phosphorylase Relevance to chemotherapy . Cancer Chemother Pharmacol. 45:2000;351-361.
16. Martin D.S., Stolfi R.L., Sawyer R.C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol. 24:1989;9-14.
17. Cradock J.C., Vishnuvajjala B.R., Chin T.F., Hochstein H.D., Ackerman T.K. Uridine-induced hyperthermia in the rabbit. J Pharm Pharmacol. 38:1986;226-229.
18. Peters G.J., van Groeningen C.J., Laurensse E.J., Lankelma J., Kraal I., Leyva A., Lankelma J., Pinedo H.M. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm Res. 4:1987;113-119.
19. Peters G.J., van Groeningen C.J., Laurensse E.J., Lankelma J., Leyva A., Pinedo H.M. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol. 20:1987;101-108.
20. Falcone A., Darnowski J.W., Puprecht R.M., Chu S.H., Burnetti I., Calabresi P. Differential effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. Blood. 76:1990;2216-2221.
21. Gasser T., Moyer J.D., Handschumacher R.E. Novel single pass exchange of circulating uridine in rat liver. Science. 213:1981;777-778.
22. Moyer J.D., Oliver J.T., Handschumacher R.E. Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41:1981;3010-3017.
23. Monks A., Ayers O., Cysyk R.L. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem Pharmacol. 32:1983;2003-2009.
24. Darnowski J.W., Handschumacher R.E. Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. Pharmacol Ther. 41:1989;381-392.
25. Dahnke H.-G., Mosebach K.-O. In-vivo-Untersuchungen zur Metabolisierung der Pyrimidinnucleoside. Hoppe Seylers Z Physiol Chem. 356:1975;1565-1574.
26. Holstege A., Leser H.-G., Pausch J., Gerok W. Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes. Eur J Biochem. 149:1985;169-173.
27. Holstege A., Pausch J., Gerok W. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidney. Cancer Res. 46:1986;5576-5581.
28. Holstege A., Gengenbacher H.-M., Jehle L., Gerok W. Uridine catabolism by the isolated perfused rat liver. J Hepatol. 14:1992;335-341.
29. Darnowski J.W., Handschumacher R.E. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res. 45:1985;5364-5368.
30. Davis S.T., Joyner S.S., Chandrasurin P., Baccanari D.P. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. Biochem Pharmacol. 45:1993;173-181.
31. Pizzorno G., Yee L., Burtness B.A., Marsh J.C., Darnowski J.W., Chu M.Y.W., Chu S.H., Chu E., Leffert J.J., Handschumacher R.E., Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res. 4:1998;1165-1175.
32. Darnowski J.W., Handschumacher R.E., Wiegand R.A., Goulette F.A., Calabresi P. Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine. Biochem Pharmacol. 41:1991;2031-2036.
33. Kelsen D.P., Martin D., O'Neil J., Schwartz G., Saltz L., Sung M.T., von Borstel R., Bertino J. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol. 15:1997;1511-1517.
34. Naguib F.N.M., Levesque D.L., Wang E.-C., Panzica R.P., el Kouni M.H. 5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem Pharmacol. 46:1993;1273-1283.
35. Levesque D.L., Wang E.-C., Wei D.-C., Tzeng C.-C., Panzica R.P., Naguib F.N.M., el Kouni M.H. Synthesis of a new class of uridine phosphorylase inhibitors. J Heterocycl Chem. 30:1993;1399-1404.
36. el Kouni M.H., Naguib F.N.M., Park K.S., Cha S., Darnowski J.W., Soong S.-J. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem Pharmacol. 40:1990;2479-2485.
37. Naguib F.N.M., Soong S.-J., el Kouni M.H. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem Pharmacol. 45:1993;667-673.
38. Naguib F.N.M., Hao H.-N., el Kouni M.H. Potentiation of 5-fluorouracil antineoplastic activity by the dihydrouracil dehydrogenase inhibitor 5-benzyloxybenzyluracil. Cancer Res. 54:1994;5166-5170.
39. ′-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. Cancer Res. 55:1995;1092-1098.